Valneva to provide 40,000 IXCHIQ doses in France starting early April
PremiumThe FlyValneva to provide 40,000 IXCHIQ doses in France starting early April
12d ago
Valneva files prospectus for sale of up to $350M shares
Premium
The Fly
Valneva files prospectus for sale of up to $350M shares
12d ago
Valneva price target lowered to $15 from $17 at Guggenheim
Premium
The Fly
Valneva price target lowered to $15 from $17 at Guggenheim
13d ago
Valneva SE to Present at Key Healthcare Investor Conferences
PremiumCompany AnnouncementsValneva SE to Present at Key Healthcare Investor Conferences
1M ago
Valneva Gains EMA Support for Chikungunya Vaccine Extension
Premium
Company Announcements
Valneva Gains EMA Support for Chikungunya Vaccine Extension
1M ago
Valneva reports positive CHMP opinion for adolescent label extension for Ixchiq
Premium
The Fly
Valneva reports positive CHMP opinion for adolescent label extension for Ixchiq
1M ago
MHRA grants Valneva marketing authorization for chikungunya vaccine
PremiumThe FlyMHRA grants Valneva marketing authorization for chikungunya vaccine
2M ago
Valneva’s Vaccine Market Expansion and Revenue Growth Drives Buy Rating with $18 Price Target
Premium
Ratings
Valneva’s Vaccine Market Expansion and Revenue Growth Drives Buy Rating with $18 Price Target
2M ago
Valneva’s Chikungunya Vaccine Gains UK Approval, Expanding Global Reach
Premium
Company Announcements
Valneva’s Chikungunya Vaccine Gains UK Approval, Expanding Global Reach
2M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100